Showing results (81-90 of 223) with videos related to

Sort By:
Pageof 23
Future Oncology (London, England)|July 19, 2022
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemiaVladimir Ivanov, Su-Peng Yeh, Jiri Mayer, et al.
Bone Marrow Transplantation|August 9, 2018
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysisVipul Sheth, Myriam Labopin, Jonathan Canaani, et al.
Mycoses|March 21, 2012
Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experienceZdenek Racil, Jana Winterova, Michal Kouba, et al.
Carcinogenesis|December 6, 2013
Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemiaJana Kminkova, Marek Mraz, Kristina Zaprazna, et al.
Molecular Oncology|January 22, 2025
Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantationDaniel Busa, Zdenka Herudkova, Jan Hyl, et al.
European Journal of Haematology|November 21, 2008
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabineSona Cejkova, Ludmila Rocnova, David Potesil, et al.
Annals of Hematology|February 26, 2011
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patientsMichael Fiegl, Florian Falkner, Michael Steurer, et al.
Leukemia & Lymphoma|November 27, 2014
Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?Andrea Janikova, Zbynek Bortlicek, Vit Campr, et al.
Cellular and Molecular Life Sciences : CMLS|December 11, 2019
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complexTomas Gregor, Michaela Kunova Bosakova, Alexandru Nita, et al.
Journal of Hematology & Oncology|December 19, 2024
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE studyTimothy P Hughes, Giuseppe Saglio, Jan Geissler, et al.
Pageof 23